Résumé
OBJECTIVE:To observe therapeutic efficacy and safety of telbivudine combined with adefovir dipivoxil in long-term treatment of active hepatitis B cirrhosis. METHODS:76 patients with active hepatitis B cirrhosis in our hospital were ran-domly divided into observation group and control group,with 38 cases in each group. Control group was treated with adefovir dip-ivoxil 10 mg,qd;observation group was additionally treated with telbivudine 600 mg,qd,on the basis of control group. Both groups received 2-year consecutive treatment. TBIL,ALB,ALT,AST,rate of HBV-DNA negative conversion and serum virologi-cal index were compared between 2 groups after treatment,and clinical efficacy and ADR were also compared between 2 groups. RESULTS:After treatment,the levels of AST,ALB,ALT and TBIL in observation group were significantly better than the control group,with statistical significance(P<0.05);the rate of HBV-DNA negative conversion,the decreased of serum virus in observa-tion group were significantly higher than control group after 1 and 2 years treatment,with statistical significance(P<0.05). The to-tal effective rate of observation group was significantly higher than that of control group,with statistically significance(P<0.05). No obvious ADR was found in 2 groups. CONCLUSIONS:Telbivudine combined with adefovir dipivoxil can significantly improve the liver function of patients with hepatitis B cirrhosis and have good long-term therapeutic efficacy with high safety.